Evidence map›Paper›PMID 40312677›Full record

Trial reportBMC musculoskeletal disorders2025

Supplemental nucleus pulposus allograft in patients with lumbar discogenic pain: results of a prospective feasibility study.

Douglas P Beall, Timothy T Davis, Kasra Amirdelfan, Ramana K Naidu, Michael J DePalma, Shrif Costandi, Edward S Yoon, Jacob W Fleming, Jon E Block, Nagy Mekhail

Registry-linked trialAbstract readMulticenter StudyClinical Trial
In one paragraph

Trial report in BMC musculoskeletal disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05201287 (A Pilot Study Evaluating the Safety and Clinical Effectiveness of Nucleus Pulposus Allograft for Supplementation of Nucleus Pulposus Tissue in Patients With Symptomatic Degenerated Discs), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05201287 naunknown statusnot on this map

A Pilot Study Evaluating the Safety and Clinical Effectiveness of Nucleus Pulposus Allograft for Supplementation of Nucleus Pulposus Tissue in Patients With Symptomatic Degenerated Discs

TypeinterventionalSponsorVIVEX Biologics, Inc.Ran2021 to 2024Enrolled35ConditionsDegenerative Disc Disease, Low Back Pain, Disc DegenerationArmsVIA Disc NP
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Douglas P BeallComprehensive Specialty Care, 1023 Waterwood Pkwy, Edmond, OK, 73034, USA.
Timothy T DavisSource Healthcare, 2801 Wilshire Blvd, Ste. A, Santa Monica, CA, 90403, USA.
Kasra AmirdelfanBoomerang Healthcare, Inc, 450 N. Wiget Lane, Walnut Creek, CA, 94598, USA.
Ramana K NaiduMarinHealth Spine Institute, 2 Bon Air Road, Ste. 120, Larkspur, CA, 94939, USA.
Michael J DePalmaVirginia iSpine Physicians, 12874 Patterson Avenue, Ste. A, Richmond, VA, 23238, USA.
Shrif CostandiCleveland Clinic, 9500 Euclid Avenue, Cleveland, OH, 44195, USA.
Edward S YoonHospital for Special Surgery, 535 East 70 Street, New York, NY, 10021, USA.
Jacob W FlemingVascular and Interventional Specialists, Dallas, TX, USA.
Jon E Block, 2210 Jackson Street, Ste. 401, San Francisco, CA, 94115, USA. jb@drjonblock.com.
Nagy MekhailCleveland Clinic, 9500 Euclid Avenue, Cleveland, OH, 44195, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDegeneration of the intervertebral disc is a significant source of chronic axial low back pain. Direct supplementation of degenerated nucleus pulposis (NP) tissue with intradiscally delivered allogeneic NP represents an opportunity to bridge the treatment gap between failed conservative care and spine surgery for patients with lumbar discogenic pain.

methodsProspective, single-arm clinical study conducted at 6 sites in the US. The primary objective was to determine the magnitude of improvement in back pain severity and back function in patients with chronic lumbar discogenic pain at 12 months after a single intradiscal supplementation procedure using a commercially available NP allograft at up to two vertebral levels identified on magnetic resonance imaging. Back pain severity was evaluated using an 11-point numeric rating scale (NRS) and back function using the Oswestry Disability Index (ODI). Minimal clinically important difference (MCID) and substantial clinical benefit (SCB) were set at ≥ 30% and ≥ 50% over baseline, respectively. The patient acceptable symptom state (PASS) threshold for pain severity was ≤ 3.

resultsTwenty-eight participants with a mean age of 44 ± 13 yrs. were enrolled and 22 provided 12-month outcomes. The average overall improvement in back pain severity was 43% through 12 months (p < 0.001). Approximately 64% (14 of 22) achieved the MCID in back pain at 12 months, with 55% (12 of 22) realizing SCB. Almost 60% (13 of 22) reported a 12-month back pain severity score of ≤ 3. The corresponding average decrease in ODI values was 50% (p < 0.001) with approximately 59% (13 of 22) of study participants achieving the MCID. At baseline approximately 82% (23 of 28) of participants reported severe or crippled back impairment compared to 18% (4 of 22) at 12 months (p < 0.001).

conclusionThe results of this study provide additional evidence that supplementation of the degenerated intervertebral disc with intradiscally delivered allogeneic NP is associated with clinically significant pain palliation and functional improvement.

trial registrationThis trial was prospectively registered at ClinicalTrials.gov on December 30, 2021 (NCT05201287).

Indexed as

Intervertebral Disc DegenerationLow Back PainLumbar VertebraeNucleus PulposusAdultAllograftsFeasibility StudiesFemaleHumansMagnetic Resonance ImagingMaleMiddle AgedPain MeasurementPilot ProjectsProspective StudiesTransplantation, HomologousAllograftBack painDegenerative disc diseaseDiscogenicIntradiscalNucleus pulposus

Identifiers

PMID40312677
PMCPMC12044970

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.